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Abstract
Background: Fingolimod (FTY720) is an immunomodulating drug that inhibits sphingosine-1-phosphate binding
and blocks T-cell egress from lymph nodes. We analyzed the effect of FTY720 on the autoimmune T- and B-cell
response in autoimmune arthritis and studied the mechanisms by which it alters the function of T cells.
Methods: Human leukocyte antigen (HLA)-DR1 humanized mice were immunized with type II collagen (CII) and
treated with FTY720 three times per week for 3 weeks. Arthritis was evaluated and autoimmune T- and B-cell
responses were measured using proliferation assays, enzyme-linked immunosorbent assays, HLA-DR tetramers, and
flow cytometry. The functional capacity of regulatory T (Treg) cells from FTY720-treated mice was measured using
an in vitro suppression assay, and the role of Treg cells in inhibiting arthritis in FTY720-treated mice was evaluated
using mice treated with anti-CD25 to deplete Treg cells.
Results: Treatment with FTY720 delayed the onset of arthritis and significantly reduced disease incidence. FTY720
did not prevent the generation of a CII-specific autoimmune T-cell response in vivo. However, as the treatment
continued, these T cells became unresponsive to restimulation with antigen in vitro, and this anergic state was
reversed by addition of interleukin 2. Measurements of CD4+CD25+Foxp3+ cells in the lymph nodes revealed that
the ratio of Treg to helper T (Th) cells increased twofold in the FTY720-treated mice, and in vitro assays indicated
that the regulatory function of these cells was enhanced. That FTY720 stimulation of Treg cells played a major role
in arthritis inhibition was demonstrated by a loss of disease inhibition and restitution of the T-cell proliferative
function after in vivo depletion of the Treg cells.
Conclusions: While FTY720 affects the recirculation of lymphocytes, its ability to inhibit the development of
autoimmune arthritis involves several mechanisms, including the enhancement of Treg cell function by increasing the
Treg/Th ratio and increased regulatory function on a per-cell basis. FTY720 did not inhibit the development of the
autoimmune T-cell response, but disease inhibition appeared to be mediated by Treg cell–mediated suppression of the
CII-specific T cells. These data suggest that specific targeting of Treg cells with FTY720 may be a novel therapy for
autoimmunity.
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Background
Autoimmunity is often considered a disease of immune
imbalance between autoreactive helper T (Th) cells and
regulatory T (Treg) cells. While thymic selection deletes
the vast majority of autoreactive T cells during their mat-
uration, a small but significant number of these autoreac-
tive T cells survive thymic negative selection and reside in
peripheral lymphoid tissue, where, under the right condi-
tions, they can become activated and induce an auto-
immune disease. Treg cells expressing the transcription
factor Foxp3 play a major role in preventing activation
and disease induction by these autoimmune Th cells, and
maintaining a physiological balance between these two
populations of cells is a major factor in preventing auto-
immunity [1, 2]. Several investigators have demonstrated
that when Treg cells are functionally deficient or absent in
mice and humans, a variety of autoimmune disorders will
develop [3–7]. Support for the role of Treg cells in pre-
venting autoimmunity has been demonstrated in a num-
ber of studies where the administration of exogenously
derived Treg cells inhibited the development of auto-
immunity in several animal models [8–13]. Consequently,
considerable efforts are being made to develop therapeutic
means to inhibit autoimmune T-cell function by augment-
ing Treg cell numbers and/or their function.
One drug that has been studied for its ability to down-
regulate an autoimmune T-cell response is fingolimod
(FTY720). FTY720 is an immunomodulatory drug that is
structurally similar to sphingosine-1-phosphate (S1P), a
lysophospholipid that affects a wide range of physiological
activities, including lymphocyte trafficking and function
[14, 15]. One of the immunomodulatory roles of S1P is its
promotion of the egress of lymphocytes from the lymph
nodes (LNs) to the bloodstream via the lymphatics [14].
Acting as an antagonist or partial agonist, FTY720 pre-
vents S1P binding to its receptor and downregulates the
receptor expression and signaling [16, 17]. The net effect
is that lymphocyte recirculation from the LNs is blocked,
causing lymphocytes to remain in the LNs and the periph-
eral blood to become lymphopenic [14]. As an immuno-
modulatory agent, FTY720 has been shown to have
beneficial effects in several animal models in which T cells
directly mediate the pathology, including experimental
autoimmune encephalomyelitis (EAE) [18], diabetes [19],
and inflammatory bowel disease [20]. However, it is less
effective in other autoimmune disease models, such as
systemic lupus erythematosus (SLE), where antibody pre-
dominates as the pathogenic mechanism [21]. Clinically,
FTY720 has been approved as a treatment for relapsing
multiple sclerosis [22, 23]. On the basis of its ability to
inhibit the function of S1P promotion of lymphocyte re-
circulation, it was initially thought that the primary mech-
anism of autoimmune disease inhibition by FTY720 was
the sequestration of T cells to secondary lymphoid organs,
thereby preventing the movement of lymphocytes to the
tissues targeted by the autoimmune T cells. However, re-
cent studies have indicated that, in addition to sequestra-
tion, FTY720 treatment appears to drive down Th cell
function and promote the activity and/or number of nat-
ural regulatory T (nTreg) cells [20, 24]. These observa-
tions have put a new focus on the mechanisms of FTY720
as a therapeutic agent of autoimmunity.
Using a human leukocyte antigen (HLA)-DR1 trans-
genic (Tg) mouse model of rheumatoid arthritis (RA), we
investigated the ability of FTY720 to inhibit the develop-
ment of autoimmune arthritis induced by immunization
with type II collagen (CII). Given that disease manifest-
ation in this model is dependent on an autoimmune T-
and B-cell response, we sought to determine if FTY720
would be effective in preventing an autoimmune response
where autoantibody plays a major role. Our studies indi-
cate that while FTY720 inhibits the development of auto-
immune disease in this model, its effect on B cells and T
cells differs significantly. Our data indicate that FTY720
not only differentially modulates the migration of lympho-
cytes via the lymphatics but also enhances Treg function
and alters the Th/Treg balance to a level sufficient to in-
hibit the function of autoimmune T cells and prevent the
development of autoimmune arthritis.
Methods
Mice
The generation of DRB1*0101 Tg mice (DR1) has previ-
ously been described [25]. The human DRA1 and DRB1
transgenes were established in (C57BL/6 × SJL/J)F2 mice
and backcrossed to the B10.M background, and the mur-
ine I-Af molecule expressed by B10.M mice was genetically
deleted by backcrossing the B6.129S2-H2dlAb1-Ea/J knock-
out (stock number 003584; The Jackson Laboratory, Bar
Harbor, ME, USA) onto the B10.M-DR1 strain for six gen-
erations. A DR1 mouse expressing a CII-specific T-cell re-
ceptor (TCR) transgene was established using the cassette
vectors pTαcass and pTβcass (gift of Dr. C. Benoist and
Dr. D. Mathis, Harvard Medical School, Boston, MA, USA
[26]). The rearranged T-cell receptor Vα2/Jα27 and Vβ8.1/
Dβ1/Jβ2.4 fragments were derived from a DR1-restricted,
CII259–274-specific T-cell hybridoma (E168) by polymerase
chain reaction (PCR), cloned into PCR2.1, and confirmed
by sequencing. These complementary DNA were sub-
cloned into the expression vectors, generating pTαcass-
Vα2 and pTβcass-Vβ8.1. The transgenes were established
by injecting both genes into fertilized eggs of FVB/N mice.
Tg founders were identified by PCR analysis of tail DNA,
and transmission of the transgenes to subsequent
generations was ascertained by PCR or flow cytomet-
ric analysis using peripheral blood lymphocytes. Mice
were backcrossed onto the B10.M-DR1 mice to estab-
lish a B10.M-DR1-TCR Tg mouse strain. Mice used in
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these experiments were from generations N7–N9, and
they were heterozygous for the TCR transgenes and
homozygous for the HLA-DR1 transgene. All mice
used in these studies were bred in our own facility,
maintained in microisolators in a pathogen-free envir-
onment, and fed standard rodent chow (Nestlé Purina, St.
Louis, MO, USA) and water ad libitum. All animal studies
were approved by the Institutional Animal Care and
Use Committee and the Research and Development
Committee at the Memphis VA Medical Center,
Memphis, TN, USA.
Immunizations and arthritis
For arthritis induction and T-cell proliferation assays, 8- to
10-week-old mice were immunized subcutaneously at the
base of the tail with 100 μg of bovine CII emulsified in
complete Freund’s adjuvant (CFA) consisting of 85 % heavy
paraffin oil (Fisher Scientific, Fair Lawn, NJ, USA), 15 %
mannide monooleate (Sigma-Aldrich, St. Louis, MO,
USA), and 4 mg/ml of heat-killed mycobacterium (Difco
H37Ra; BD Diagnostics, Sparks, MD, USA) [27]. FTY720
(Cayman Chemical, Ann Arbor, MI, USA) was diluted in
nitrogen-bubbled 10 % ethanol and injected intraperitone-
ally. Treatment schemes varied among experiments and
are described in the Results section. In some experiments,
mice were treated with 250 μg of rat anti-CD25 (clone
PC61) or a control rat antibody (MOPC 167) once weekly
for 3 weeks. Peripheral blood was monitored by flow cy-
tometry to ensure efficacy in the depletion of the CD25
+Foxp3+ T cells. For arthritis studies, mice were examined
three times per week starting at day 18 after immunization,
and the presence of arthritis, number of affected limbs,
and severity of inflammation were assessed. Severity of dis-
ease was evaluated by visual inspection and assigned a
score using a scale of 0–4 as described elsewhere [27].
Measurement of antibody levels
CII-specific antibody levels in sera of mice immunized with
CII/CFA were quantitated using a bead-based enzyme-
linked immunosorbent assay and a Bio-Plex instrument
(Bio-Rad Laboratories, Hercules, CA, USA). Fluorescent
dye–labeled beads coupled with bovine CII were incubated
with dilutions of mouse sera starting at 1:1000, and the
quantity of bound mouse immunoglobulin G (IgG) was
detected by the addition of a biotinylated anti-mouse
IgG (Sigma-Aldrich) followed by phycoerythrin (PE)-
streptavidin (Invitrogen, Carlsbad, CA, USA). The quantity
of anti-CII antibody was calculated using a curve gener-
ated with purified CII-specific antibody as the standard.
Antibodies and flow cytometry
Fluorescently labeled antibodies specific for CD3 (Alexa
Fluor 700; Life Technologies, Carlsbad, CA, USA), CD4
(PE or Pacific Blue), CD8 (allophycocyanin [APC]), CD19
(peridinin chlorophyll-cyanine 5.5 [PerCP-Cy5.5]), CD25
(PerCP-Cy7), and CD62L (fluorescein isothiocyanate
[FITC]) were obtained from BD Biosciences (San Jose,
CA, USA). Intracellular staining for Foxp3 was performed
using anti-mouse Foxp3 antibody labeled with FITC ac-
cording to the manufacturer’s instructions (eBioscience,
San Diego, CA, USA). Labeled cells were washed with
phosphate-buffered saline (PBS), and a minimum of
10,000 cells were analyzed from each sample using a 5-
laser (355, 405, 488, 561, and 640 nm) BD LSR II flow cyt-
ometer (BD Biosciences). To determine cell numbers,
50 μl of Molecular Probes CountBright beads (Thermo
Fisher Scientific, Eugene, OR, USA) were added to each
sample before cytometric analyses, and the number of
cells per unit volume was calculated as (cell events/bead
events) × (bead count/volume of blood sample analyzed).
Data analysis was performed using FlowJo software (Tree
Star, Ashland, OR, USA).
Tetramer binding
CII-specific T cells from draining LNs were enumerated
and characterized using a DR1-CII tetramer [28]. Briefly,
soluble DR1 covalently linked to the immunodominant
CII peptide was produced in S2 cells, affinity-purified,
biotinylated by BirA (Avidity, Aurora, CO, USA), and
formed into multimeric units by stepwise addition of
PE-labeled streptavidin (Rockland Immunochemicals,
Limerick, PA, USA). For identification of CII-specific T
cells ex vivo, LN cells were incubated with 1 μg of the
tetramer at 37 °C for 2.5 h in complete HL-1 medium
(50 U/ml penicillin G sodium, 50 μg/ml streptomycin
sulfate, 0.05 mM β-mercaptoethanol, 2 mM L-glutamine,
and 0.1 % bovine serum albumin; BioWhittaker/Lonza,
Walkersville, MD, USA) supplemented with 5 mM
NaN3. At the end of the incubation, antibodies specific
for various CD markers were added and cells were incu-
bated for an additional 30 minutes at 4 °C. Samples were
then washed and resuspended in PBS supplemented with
0.1 % NaN3 and 2 % fetal bovine serum and analyzed by
flow cytometry (BD LSR II). DR1-restricted, CII257–274-
specific and HA306–318-specific T-cell hybridomas were
used as positive and negative controls, respectively, to
monitor the specificity and sensitivity of the DR1-CII
tetramer (see Additional file 1).
T-cell proliferation and Treg assays
Total lymphocytes or CD4+CD25− T cells were recov-
ered from draining LNs of CII-immunized mice treated
with FTY720 or vehicle and cultured in the presence of
the CII257–274 peptide and antigen-presenting cells for
4 days. T-cell proliferation assays were performed in 96-
well microtiter plates in a total volume of 0.3 ml con-
taining 4 × 105 LN cells and various concentrations of
the CII257–274 peptide in complete HL-1 medium. For
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experiments using purified CD4+ T cells, equal numbers
of naive spleen cells were added as antigen-presenting
cells. Cell cultures were maintained at 37 °C in 5 % hu-
midified CO2 for 4 days. On day 3 of culture, 1 μCi of
[3H]thymidine was added, and on day 4 the plates were
harvested onto filter plates. After the filter plates were
dried, scintillation fluid was added and [3H]thymidine
incorporation was measured using a TopCount NXT in-
strument (PerkinElmer, Waltham, MA, USA).
Treg cell assays were performed using Treg cells puri-
fied with an autoMACS separator (Miltenyi Biotec, San
Diego, CA, USA), and CII-specific T cells as responders
were recovered from the B10.M-DR1-TCR Tg mouse.
Treg cells were purified from LN cells of mice treated
with FTY720 or vehicle by negative selection for CD4+
T cells and positive selection for CD25+ T cells (Miltenyi
Biotec). The quality of the purification was monitored
using antibodies specific for CD4, CD25, and Foxp3 and
by flow cytometric analysis (BD LSR II). The negative se-
lection resulted in ≥85 % enrichment of CD4+ cells, and
positive selection yielded CD4+CD25+ cells at ≥95 %.
Splenocytes containing Tg CII-specific T cells were used
as the responders in the Treg assays and were labeled
with 2.5 μM CellTrace Violet as described by the manu-
facturer (Invitrogen) before their addition to the Treg as-
says. The Treg cells and the labeled T responders were
cocultured in 96-well plates at ratios of 1:1 to 1:16 Treg/
T responder cells in the presence of 10 μg of CII257–274
peptide. After 3 days of culture, cells were recovered from
the cultures; stained with 4′,6-diamidino-2-phenylindole
(DAPI; Sigma-Aldrich) and antibodies specific for CD19
(PerCP-Cy5.5), CD8-APC, CD4-PE, and CD3-Alexa Fluor
700 (BD Biosciences); and analyzed by flow cytometry.
Our data analysis was based on sequential gating of live
cells (DAPI-negative), low angle versus side scatter, CD8−
and CD19−, CD3+, and CD4+ cells. Generations of T-cell
division were determined by generational dilution of the
CellTrace Violet dye, and gates were drawn to determine
the percentage of responder T cells that were in cellular
division.
Cell-mixing proliferation experiments were performed
as described above using purified CII-specific T cells and
antigen-presenting cells from LN cells of mice treated
with FTY720 or vehicle. The DR1-TCR Tg mouse was
used as the source of CII T cells. The T cells were purified
using an autoMACS instrument as described above. The
antigen-presenting cell population was collected as a
negative selection population following T-cell depletion.
All purifications were monitored for quality by flow
cytometry to ensure depletion of Treg cells, positive selec-
tion of CD4+CD25− cells, and enrichment for antigen-
presenting cells. The purified antigen-presenting cell and
T-cell populations were recombined in culture in all pos-
sible permutations and stimulated with CII peptide, and
proliferation was measured by [3H]thymidine incorpor-
ation as described above.
Results
FTY720 inhibits the development of autoimmune arthritis
To determine the effect of FTY720 on the development
of autoimmune arthritis, DR1 Tg mice immunized with
CII/CFA were treated with 1 mg/kg or 0.2 mg/kg of
FTY720 every 3 days for a total of nine treatments over
3 weeks, and arthritis incidence and severity were evalu-
ated. As shown in Fig. 1, both doses of FTY720 signifi-
cantly inhibited arthritis development. Animals receiving
FTY720 had reduced incidence and delayed onset of dis-
ease (Fig. 1a), and the severity of disease was also signifi-
cantly reduced (Fig. 1b and c). The mean times of onset
of disease for the FTY720 groups were day 42 and day
40 (1 mg/kg and 0.2 mg/kg, respectively), as opposed to
day 33 for the control group (p < 0.03 for both groups),
and FTY720 treatment decreased the incidence of arth-
ritis by as much as 50 % (1 mg/kg) (Fig. 1a). The severity
of disease in terms of arthritic limbs per arthritic mouse
and mean severity score per arthritic mouse was also
significantly decreased in animals that received the drug
(Fig. 1b and c). The three initial time points for the
1 mg/kg group depicted in Fig. 1b and c (days 35, 37,
and 39) were based on only one arthritic mouse and two
limbs at each of these time points, making comparison
of these early evaluations of severity less reliable. As the
incidence of arthritis increased in the 1 mg/kg group at
the later time points, the mean severity of disease per
mouse dropped to 50 % of that observed in the control
group. While CII-specific autoantibody concentrations
were also significantly lower in the FTY720-treated mice
(Fig. 1d), appreciable concentrations of autoantibody
were detected in both FTY720 groups at both time
points. These data are consistent with the arthritis inci-
dence data (Fig. 1a) in that while arthritis was delayed in
the FTY720 groups, some mice eventually developed
disease.
FTY720 alters the number and subpopulation distribution
of B and T cells in the peripheral blood and lymph nodes
To determine how the autoimmune response was af-
fected by FTY720, peripheral blood and draining LNs
from mice treated with the drug or control vehicle were
analyzed for lymphocyte numbers and composition. As
reported elsewhere [14, 29, 30], treatment of mice with
FTY720 greatly reduced the number of B and T lympho-
cytes in the peripheral blood (22 % and <2 % of levels in
control mice, respectively), but it also altered the
lymphocyte subset distributions (Fig. 2). After 24 h, the
total number of circulating B and T cells dropped dra-
matically (Fig. 2a) and the number of CD3+CD4+ and
CD3+CD8+ cells were similarly decreased (Fig. 2b). The
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composition of the lymphocyte subpopulations that
remained in the circulation of the FTY720-treated mice
was altered compared with the vehicle control group.
While the percentage of CD19+ B cells in the total
lymphocyte population in the peripheral blood dropped
by 50 % after treatment with FTY720 (Fig. 2c), the CD3+
T-cell population was reduced to <5 % of levels found in
vehicle-treated mice (Fig. 2d). These changes were primar-
ily the result of decreases in the CD4+ subpopulation; the
percentage of CD8+ T cells was relatively unchanged
(Fig. 2e and f). Thus, while FTY720 induced a significant
decrease in the total number of lymphocytes in the per-
ipheral blood, it also altered the CD4/CD8 T-cell ratio.
While one of the known functions of FTY720 is to
block the recirculation of lymphocytes from the LNs to
the blood by preventing the binding of S1P [31], we
found no concomitant increase in the number of lym-
phocytes in the draining LNs of the drug-treated mice
(Fig. 3). As in the peripheral blood, LNs from immu-
nized mice treated with FTY720 contained fewer total
lymphocytes than LNs from immunized mice treated
with vehicle (Fig. 3a), and the subpopulation distribution
of lymphocytes was also altered (Fig. 3b and c). FTY720
treatment resulted in an increase in the percentage of
CD19+ cells and a decrease in the percentage of CD3+
cells (Fig. 3b), leading to a change in the CD3/CD19 ra-
tio from 3.2:1 in vehicle-treated mice to 1.2:1 in
FTY720-treated mice. Similarly, the ratio of CD4+ to
CD8+ Tcells was also altered, but not to the degree observed
in the peripheral blood. The percentage of CD3+CD4+ cells
decreased from 65 % in the vehicle group to 53 % of the total
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Fig. 1 Treatment of mice with FTY720 reduces incidence and severity of autoimmune arthritis. DR1 transgenic mice were immunized
subcutaneously with 100 μg of type II collagen (CII) emulsified in complete Freund’s adjuvant, and they were given intraperitoneal injections of
FTY720 or vehicle control three times per week for 3 weeks starting on the day of immunization (day 0), for a total of nine injections. a FTY720 at
1.0 mg/kg (open circles) and 0.2 mg/kg (gray circles) delayed the onset of disease (mean day 33 for control and days 40 and 42 for FTY720 groups;
p < 0.03 for both groups) and reduced the disease incidence (p < 0.05 for days 30 through 40 for 1 mg/kg group, indicated by closed stars) in
comparison to the vehicle control group (closed circles; n = 11 for each group). b Both doses of FTY720 reduced the number of arthritic limbs
observed per arthritic mouse. Closed stars indicate p < 0.05. c Both doses of FTY720 reduced the mean arthritic score per arthritic mouse. Closed
stars indicate p < 0.05. d FTY720 treatment reduced the production of CII-specific autoantibody. Antibody concentrations in sera obtained from
the mice at days 30 and 50 after immunization were measured using a bead-based enzyme-linked immunosorbent assay, and antibody concentrations
were calculated using a CII-specific antibody standard. Closed stars indicate p < 0.05; error bars indicate standard deviation
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increased marginally, from 27 % to 34 % of the CD3+ cells
(Fig. 3c).
FTY720 does not inhibit the generation of the
autoreactive T-cell response in vivo
Because FTY720 has a strong effect on CD4+ T-cell recir-
culation, and because collagen-induced arthritis is mediated
by CII-specific CD4+ T cells [28], we investigated how
FTY720 affected the development of the CD4+ CII-specific
autoimmune T-cell response in the DR1 Tg mice (Fig. 4).
LN cells were recovered from CII-immunized mice treated
with FTY720 or vehicle as described for Fig. 1, as well as in
unimmunized mice, and the number of CII-specific T cells
present was determined using a PE-labeled DR1-CII tetra-
mer in combination with fluorescently labeled antibodies

































































Fig. 2 FTY720 (FTY) treatment alters the number and ratio of lymphocyte populations in the peripheral blood of type II collagen–immunized
mice. Peripheral blood lymphocytes (PBLs) were recovered from mice treated with FTY720 at 24 h, 72 h, and 120 h after a single 1 mg/kg
treatment, and the cells were stained with antibodies specific for CD19, CD3, CD4, and CD8. All data were gated on the basis of live cells
(4′,6-diamidino-2-phenylindole–negative) and forward versus side scatter to identify the lymphoid population. The CD4+ and CD8+ populations
were generated as subpopulations of CD3+ cells. a and b The number of cells per microliter of blood was determined by adding CountBright
beads to the samples before analyses, as described in the Methods section. Closed stars in (a) indicate statistically significant changes (p < 0.01).
c–f Change in the subpopulation distribution of B cells and T cells in the peripheral blood. Antibody staining and analysis of the flow cytometry
data were done as indicated in each panel, with statistically significant differences of p < 0.05 denoted by closed stars. Open bars indicate 1.0 mg/kg
FTY720 treatment, and closed bars represent vehicle control. Error bars depict standard deviations













































Fig. 3 FTY720 treatment alters the total cell number and ratio of lymphocyte populations in the draining lymph nodes (LNs) of type II collagen–
immunized mice. Cells were recovered from draining LNs after immunization and nine treatments with FTY720 as described in the Fig. 1 legend.
The number of cells in the LNs of FTY720-treated mice was significantly lower than the number found in the LNs of controls (a). The ratios of
B-cell and T-cell subpopulations in the LNs (b and c) were statistically different between FTY720-treated and control mice, although the differences
were significantly less than the differences observed in the peripheral blood. Antibody staining, measurement of cell numbers, and data analysis were
performed as described in the Fig. 2 legend. Closed stars indicate statistically significant differences (p < 0.05). Open bars indicate 1.0 mg/kg FTY720













































































































































Fig. 4 Ex vivo analysis of the effect of FTY720 on the type II collagen (CII)-specific T-cell response. Mice were immunized with CII and complete Freund’s
adjuvant and treated with FTY720 (1.0 mg/kg or 0.2 mg/kg) or vehicle, or they were not immunized and not treated (naive). Lymph node cells recovered
from the mice treated with FTY720 or vehicle (a–c) or from naive mice (d) were stained with a DR1-CII tetramer and antibodies specific for CD19, CD3,
CD4, CD8, CD25, and CD62L, and the cells were analyzed by flow cytometry. The mean percentage of CD4+/tetramer-positive, CII-specific T cells in the
lymph nodes is shown in (e), and the number of CII-specific T cells present in the lymph nodes as determined by tetramer staining and cell counts is
shown in (f). The expression of CD25 and CD62L by the tetramer-positive cells in the FTY720 and control groups as determined by flow cytometry is
shown in (g) and (h). Data were generated by sequential gating on 4′,6-diamidino-2-phenylindole–negative cells, forward versus side scatter, CD19− and
CD8− cells, and CD3+CD4+ cells. The tetramer-positive cells in (a–e) are shown as the percentage of CD3+CD4+ T cells, and this percentage value was
used to calculate the total number of CII-specific T cells shown in (f). Open bars indicate mice treated with 1.0 mg/kg FTY720, gray bars represent mice
treated with 0.2 mg/kg, and closed bars indicate the vehicle control group. Error bars indicate standard deviation, and p values indicate statistically
significant differences between treatment groups and vehicle groups
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on live cells using DAPI exclusion, CD19− and CD8− cells,
and CD3+CD4+, DR1-CII tetramer-positive cells (Fig. 4a–d).
FTY720 did not inhibit the development of the CD4+ CII-
specific T-cell response. In fact, the percentages of CII T
cells in both the 1.0 mg/kg and 0.2 mg/kg FTY720-treated
groups were statistically higher than those found in the
vehicle-treated control group (Fig. 4e). However, due to the
smaller total number of cells in the LNs from FTY720-
treated mice (Fig. 3a), the total number of CII-specific T
cells found in the LNs were not statistically different be-
tween these groups (Fig. 4f). Analysis of activation markers
expressed by the tetramer-positive, CII-specific T cells indi-
cated that more of the cells from the FTY720-treated mice
expressed CD25 and fewer expressed CD62L in compari-
son to the control group (Fig. 4g and h), both indications
that these T cells were stimulated by antigen in vivo.
Fig. 5 Proliferative response of type II collagen (CII)-specific T cells recovered from mice treated with FTY720 (FTY). Total lymphocytes or CD4+CD25− T
cells were recovered from draining lymph nodes of CII-immunized mice treated with 1 mg/kg of FTY720 or vehicle and cultured in the presence of
the CII257–274 peptide for 4 days. [
3H]thymidine was added to the cultures on day 3, and cells were harvested on the following day. Controls were
unstimulated cells. Error bars indicate standard deviation. a In vitro proliferative response of lymph node cells from DR1 transgenic mice immunized
with CII and treated with 1.0 mg/kg FTY720 or vehicle three times per week for 3 weeks. b Lymph node cells from mice treated with 1.0 mg/kg
FTY720 or vehicle were stimulated in vitro with anti-CD3/anti-CD28 antibodies (Ab). c Proliferative response of CD4+CD25− lymph node cells from
CII-immunized mice treated with 1.0 mg/kg FTY720 or vehicle. CD4+CD25− T cells were purified using magnetic bead separation and mixed with
antigen-presenting cells depleted of CD4+ cells recovered from the spleens of FTY720- or vehicle-treated mice. d Addition of interleukin (IL)-2 to
cultures of T cells from mice treated with FTY720 restored the CII-stimulated proliferative response. e and f DR1-CII tetramer analyses of the proliferative
response shown in (d). Lymph node cells from FTY720- or vehicle-treated mice immunized with CII were labeled with CellTrace Violet, placed in
culture, and stimulated with the CII peptide. After 3 days, cells were recovered and stained with DR1-CII tetramer; antibodies to CD3, CD4, and CD8;
and 4′,6-diamidino-2-phenylindole (DAPI). Data shown are the percentages of CD4+ DR1-CII tetramer-positive cells in cellular division as indicated
by the loss of CellTrace Violet fluorescence. Data were sequentially gated on DAPI−, CD3+, and CD8− cells. Gray histograms are the CD4+ DR1-CII
tetramer-positive cells, and open histograms are derived from CellTrace Violet–labeled cells that were not stimulated to divide
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CII-specific T cells from FTY720-treated mice are anergic
to restimulation in vitro
Despite the generation of a CII-specific T-cell response
in the draining LNs of immunized mice treated with
FTY720, these T cells were totally refractory to restimu-
lation in vitro (Fig. 5). Mice were immunized and treated
with FTY720 as described in the Fig. 1 legend, and LN
cells were collected on day 18 and stimulated with the
CII peptide CII257–275 that contains the immunodomi-
nant determinant for HLA-DR1 [25]. As depicted in
Fig. 5a, the T cells from LNs of control mice responded
strongly to peptide stimulation, while the T cells of the
FTY720-treated mice were completely unresponsive to
stimulation at all concentrations of the CII peptide
tested. FTY720 did not induce a general unresponsive-
ness in T cells, as stimulation of T cells from FTY720-
treated mice with anti-CD3 and anti-CD28 antibodies
generated a proliferative response that was indistinguish-
able from that observed with T cells from control mice
(Fig. 5b).
Cell-mixing experiments were performed to determine if
the CII-specific T cells were anergic or if FTY720-treated
antigen-presenting cells or Treg cells were suppressing or
preventing their response in vitro. Antigen-presenting cells
and CD4+CD25− CII-specific T-cell populations from
FTY720- and vehicle-treated DR1-TCR Tg mice were puri-
fied with magnetic beads, recombined in culture in all pos-
sible permutations, and stimulated with the CII peptide.
This approach effectively removed Treg cells from the cul-
tures and allowed us to determine if FTY720 altered the
function of the antigen-presenting cells or if the Tcells were
rendered unresponsive in vivo. Regardless of whether the
source of antigen-presenting cells was from FTY720-
treated mice or vehicle-treated mice, the CII-specific T cells
from FTY720-treated mice were totally unresponsive to
stimulation by antigen-presenting cell presentation of the
CII peptide (Fig. 5c). Additionally, antigen-presenting cells
from FTY720-treated mice were fully capable of stimulating
CII-specific T cells from control mice. These data indicate
that the antigen-presenting cells from FTY720-treated mice
were not preventing the antigen-specific stimulation of the
CII-specific T cells, and also that the CII-specific T cells
from the FTY720-treated mice were rendered functionally
unresponsive to restimulation in vivo. Because these experi-
ments were based on the response of identical numbers of
CD4+ T cells from both groups, these data also indicate that
the percentage decrease in CD4+ T cells observed in the
LNs of FTY720-treated mice (Fig. 3) was not responsible
for the diminished proliferative response (Fig. 5a).
To determine if the CII-specific T cells from the
FTY720-treated mice were anergic, CII-specific prolifer-
ative assays were performed in the presence of various
concentrations of exogenous interleukin (IL)-2. As
shown in Fig. 5d–f, the addition of IL-2 to these cultures
restored the proliferative response of the CII-specific T
cells from the FTY720-treated mice. The FTY720 T cells
responded in a dose-restricted manner, and their prolif-
erative response reached levels similar to levels in con-
trol T cells stimulated with the CII peptide alone
(Fig. 5a). These data are supported by tetramer analysis
of CellTrace Violet–labeled cells (Fig. 5e and f). LN cells
recovered from FTY720- and vehicle-treated mice were
labeled with CellTrace Violet and stimulated in culture
with IL-2 and CII peptide. After 3 days, cells were recov-
ered and stained with DR1-CII tetramer and antibodies
to CD3, CD4, and CD8 and analyzed by flow cytometry.
As shown in Fig. 5f, the addition of IL-2 to the CII-
stimulated cultures of lymphocytes from the FTY720-
treated mice generated a population of T cells that
bound the DR1-CII tetramer, and >75 % of these cells
were in division, as indicated by the dilution of the Cell-
Trace Violet dye. These data are similar to those ob-
served with IL-2, CII-stimulated T cells from the vehicle
control mice (Fig. 5e), in which 88 % of the CD4 + DR1-
CII tetramer-positive cells were in division. These data
support the concept that FTY720-mediated inhibition of
the development of autoimmune arthritis in this model
is mediated by an in vivo induction of anergy in the
autoimmune T cells.
Elevated ratios in vivo and enhanced function of Foxp3+
Treg cells from FTY720-treated mice
Because the CII-specific T cells from FTY720-treated mice
were unresponsive to antigen stimulation in vitro, we
sought to determine if the number or ratio of Treg cells in
FTY720-treated mice was altered in comparison to the
control mice. At days 10 and 18 after immunization and
FTY720 treatment (four doses of drug for day 10 mice,
eight doses for day 18), draining LNs were recovered and
the percentage of CD4+CD25+Foxp3+ Treg cells present
was determined by flow cytometry. Data were analyzed by
gating on CD19− and CD3+CD4+ cells, and percentages
were calculated on CD4+CD25+Foxp3+ cells (Fig. 6a and b).
As shown in Fig. 6c, 10 days after FTY720 treatment, there
was a 40 % increase in the percentage of CD25+Foxp3+
Treg cells in the LNs of these mice in comparison to the
vehicle-treated group, and by day 18 there was a 100 % in-
crease. While the drug did not induce a significant increase
in the number of Treg cells in the LNs of these mice
(Fig. 6d), it did induce a significant increase in the Treg/Th
ratio in these lymphoid organs (Fig. 6e).
Given the increased Treg/Th ratio in the mice treated
with FTY720, we evaluated the functional capacity of
these Treg cells to inhibit a CII-specific T-cell prolifera-
tive response in vitro. Treg cells enriched by a combin-
ation of negative selection for CD4+ T cells and positive
selection for CD25+ cells using magnetic beads were cul-
tured at various ratios with CII-specific T cells labeled
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with CellTrace Violet. After 3 days, cells were recovered;
labeled with fluorescent antibodies specific for CD19,
CD3, CD8, and CD4; and analyzed by flow cytometry
(Fig. 7). The data shown in Fig. 7 represent the violet
fluorochrome fluorescence intensity of the CD3+CD4+
cells, and the gates indicate the percentage of cells in
division. Figure 7f shows the proliferative response of
the CII-specific T cells in the absence of Treg cells where
89.2 % of the cells were in division. At the Treg/Th ratio
of 1:1, the Treg cells from the FTY720-treated mice
completely shut down the proliferative response of the
CII-specific T cells (Fig. 7a, left panel), while 16 % of the
CII-specific T cells were in division in the presence of
the Treg cells from the control mice (Fig. 7a, right
panel). Similarly, at each of the ratios tested through
1:16 (Fig. 8b–e), the Treg cells from the FTY720-treated
mice had significantly more regulatory capacity on a
per-cell basis than the Treg cells from the control mice
(Fig. 7g). The dose effect of the Treg cells was clearly
evident in both groups, but the Treg cells from the
FTY720 group always had a stronger regulatory effect
on the CII-specific T-cell response. Thus, not only was
the ratio of Treg/Th cells higher in the FTY720 mice
but also, on a per-cell basis, the FTY720-derived Treg












Fig. 6 The ratio of regulatory T (Treg) cells to helper T cells is increased in lymph nodes of FTY720-treated mice. Lymph node cells from DR1 transgenic
mice immunized with type II collagen and treated with FTY720 or vehicle three times per week (total of eight doses) were recovered on day 17 and
stained with antibodies specific for CD4, CD8, CD19, CD3, CD25, and Foxp3, and they were analyzed by flow cytometry. a and b Representative
scatterplots (1 mg/kg FTY720 and vehicle control, respectively) of data from at least three repeat experiments, summarized in (c). Open bars indicate
1.0 mg/kg FTY720, and closed bars represent 1.0 mg/kg vehicle control. The number of Treg cells per lymph node shown in (d) was determined using
CountBright beads as described in the Methods section. The differences observed were not statistically significant. The ratio of Treg cells to CD4+ cells
shown in (e) was calculated by dividing the number of both cell populations measured using the CountBright beads. Flow cytometry data shown
were derived from sequential gating on live cells (4′,6-diamidino-2-phenylindole–negative), forward versus side scatter, CD8− and CD19−, CD3+, and
CD4+ cells. Error bars indicate standard deviation
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To test the hypothesis that enhancement of Treg activ-
ity by FTY720 plays a role in the inhibition of auto-
immune arthritis (depicted in Fig. 1), arthritis studies
were performed with mice depleted of Treg cells and
treated with FTY720. Two days before arthritis induc-
tion, mice were treated with 250 μg of anti-CD25 (clone
PC61) or control antibody (MOPC 167) once weekly for
3 weeks. To monitor the efficacy of the antibody treat-
ment, peripheral blood samples were collected 3 days
after the first treatment and were found to be depleted
of CD4+CD25+Foxp3+ cells (Fig. 8a). Similarly, LNs were
significantly depleted of CD4+CD25+Foxp3+ Treg cells, and
the few Foxp3+ cells that remained were CD25− (Fig. 8a,
bottom panels). Starting at the time of immunization, mice
were treated three times per week with FTY720 or vehicle
as described in the Fig. 1 legend. As shown in Fig. 8b, mice
treated only with anti-CD25 developed arthritis earlier, at a
higher incidence, and with a more severe form of the dis-
ease in comparison to all groups tested. The data depicted
in Fig. 8b are a summation of two independent
Fig. 7 Functional analysis of the regulatory T (Treg) cells recovered from mice treated with FTY720. DR1 transgenic mice were immunized with
type II collagen (CII) and treated three times per week (total of eight doses) with 1.0 mg/kg of FTY720 or vehicle. On day 17, CD4+CD25+ Treg
cells were recovered from the spleens of these mice using magnetic bead selection, and they were tested for their ability to inhibit a CII-specific
T-cell proliferative response. a–e Responder T cells from naive mice were labeled with CellTrace Violet and cocultured with the Treg cells at ratios
ranging from 1:1 to 1:16 (Treg/responder) in the presence of 10 μg of CII257–274 peptide. After 3 days of culture, cells were collected and stained
with antibodies specific for CD3, CD4, CD8, and CD19 and analyzed by flow cytometry. Data shown are based on sequential gating of live cells
(4′,6-diamidino-2-phenylindole–negative), forward versus side scatter, CD8− and CD19−, CD3+, and CD4+ cells. Histograms indicate generation of
T-cell division by dilution of the CellTrace Violet label, and gates indicate percentage of responder T cells that were in division. f T-cell proliferation
with peptide added and no Treg cells added (positive control, solid line), and T cells with no Treg cells and no peptide (negative control, dotted
line). g Summary of percentage of cells dividing at each of the responder/Treg ratios. Data are representative of three independent experiments
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experiments, and they are synchronized to the first day on
which arthritis was observed in each experiment. Similarly
to the data shown in Fig. 1, treatment with FTY720 again
caused a significant delay in the onset (mean 49.6 days vs.
33.2 days for vehicle control; p < 0.015) and a significantly
lower incidence of disease in comparison to the control
group (vehicle + control antibody; p < 0.01). In comparison,
mice that received anti-CD25 and FTY720 developed a sig-
nificantly higher incidence of disease (p < 0.04 at days 24–
60) and an earlier disease onset (day 39.0; p < 0.056) than
those treated with FTY720 alone, indicating that the deple-
tion of Treg cells significantly reduced the inhibitory effect
Fig. 8 Depletion of CD25+ regulatory T (Treg) cells reduces the inhibitory effect of FTY720 on the development of autoimmune arthritis and
restores the type II collagen (CII)-specific T-cell response. Mice were immunized with CII on day 0 and split into four groups for treatment:
(1) FTY720 + anti-CD25 antibody (Ab), (2) vehicle + anti-CD25 antibody, (3) FTY720 + control antibody (MOPC 167), and (4) vehicle + control antibody.
Two days before immunization with CII, mice were treated with 250 μg of antibody (anti-CD25 or control), and antibody treatments were continued
for 3 weeks with one treatment per week. a Representative data show that anti-CD25 treatment in the Treg cell population significantly depleted the
CD25+Foxp3+ population in the peripheral blood and lymph nodes, and also significantly reduced the number of Foxp3+ cells in the lymph nodes.
Starting at the time of immunization, mice were treated with FTY720, and treatment was continued three times per week for a total of nine doses.
b Mice were scored three times per week for arthritis starting on day 18 after immunization. Data shown were derived from two separate experiments
and normalized to the first day of disease onset for each experiment. The asterisks indicate statistically significant differences in arthritis incidence
between the FTY720 + anti-CD25 group and the FTY720 + control Ab group in the study (p < 0.04 by χ2 test). c CII-specific proliferative response of
T cells from the mice presented in (b). On day 17 after immunization, cells from draining lymph nodes were placed in culture and restimulated with
the CII257–274 peptide. Proliferation was measured by [
3H]thymidine incorporation, and data are representative of two experiments. Error bars indicate
standard deviation
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of FTY720 on arthritis development. The anti-CD25 treat-
ment not only abrogated the effect of the FTY720 on arth-
ritis development but also restored the proliferative
response of the CII-specific T cells from these mice. As
shown in Fig. 8c, T cells recovered from the draining LNs
of mice treated with FTY720 and anti-CD25 had strong
proliferative responses following stimulation with the CII
peptide, while T cells from the FTY720-treated mice were
again totally unresponsive. These data support the concept
that at least one mechanism of FTY720 inhibition of arth-
ritis development in this model involves enhancement of
Treg function that downregulates the autoimmune T-cell
response.
Discussion
Earlier studies of the use of FTY720 as a therapeutic
agent for autoimmunity were focused primarily on dis-
ease models in which the pathogenesis is mediated dir-
ectly by T cells [18–20, 32]. In the present study, we
investigated the effect of FTY720 on a model of auto-
immune arthritis that requires both T and B cells for
pathogenesis, and we examined how the function of
these cells is affected by this drug. Treatment of the DR1
Tg mice with FTY720 resulted in a dose-dependent inhib-
ition of the incidence and severity of arthritis concomitant
with a reduced production of pathogenic CII-specific anti-
body. While FTY720 alters the recirculation of lympho-
cytes from the LNs to the bloodstream [14, 29, 30], our
data indicate that it had a greater effect on CD3+ cells and
a more pronounced effect on the CD4+ subpopulation.
Though FTY720 inhibited the development of arthritis,
surprisingly it did not prevent the generation of the CII-
specific autoimmune T-cell response. CII-specific T cells
were present at a higher percentage of CD4 cells in the
LNs of FTY720-treated mice compared with controls, but
in similar total numbers, and they expressed markers of
activation indicating that they had been stimulated by
antigen in vivo. Functionally, however, these T cells were
unresponsive to restimulation with antigen in vitro, an ob-
servation consistent with the lower autoantibody levels
and decreased incidence of disease. That these T cells were
anergic was demonstrated by the reversal of their unre-
sponsive state by the addition of IL-2. The unresponsive-
ness of the autoimmune T cells was coincident with an
increase in the Treg/Th cell ratio in vivo. Treg cells in the
LNs of the FTY720-treated mice constituted twice the
normal percentage found in control mice, and they were
found to be significantly more effective on a per-cell basis
in regulating Th-cell responses. That Treg cells were play-
ing a central role in the FTY720-mediated inhibition of
arthritis was supported by depletion of Treg cells in vivo
and the concomitant loss of the protective effect of
FTY720 against disease and restoration of their recall pro-
liferative response. Thus, these data indicate that a
primary mechanism by which FTY720 inhibits arthritis in
this model is through its potentiation of Treg-cell activity
that downregulates the function of autoimmune T cells.
FTY720 has been shown to be effective as an immuno-
modulatory agent to varying degrees in several models
of autoimmune disease, including EAE, diabetes, SLE,
adjuvant arthritis, and inflammatory bowel disease
[18–21, 32]. Similarly to many of these studies, treatment
of mice with FTY720 in our autoimmune arthritis model
did not completely prevent autoimmune arthritis from de-
veloping. Although the data in Fig. 1 were based on only
nine treatments following the induction of the auto-
immune response, continuous administration of FTY720
for the duration of the experiment was no more effective
than treatment through only the first 21 days (data not
shown). In both cases, disease was delayed and the inci-
dence was reduced, but some mice still generated an auto-
immune response and developed the disease. However, in
all cases, disease severity was decreased.
Initially, the primary mechanism by which FTY720 in-
hibits the development of autoimmunity was thought to
be based on its ability to prevent the recirculation of T
cells. FTY720 is a structural analogue of S1P. S1P medi-
ates lymphocyte recirculation by inducing the egress of
lymphocytes from the LNs to eventually enter the per-
ipheral bloodstream. In vivo FTY720 becomes phosphor-
ylated and binds to four of the five S1P receptors
(S1PRs), with its affinity for the S1P1R being the highest
[31, 33]. The initial effect is partial agonist activation of
the S1PR, followed by their internalization. Unable to
use S1P signaling, the T cells exposed to FTY720 be-
come trapped in the LNs, and thus it was suspected that
disease inhibition was a result of preventing the move-
ment of the pathogenic lymphocytes to the sites of in-
flammation. Our data indicate that FTY720 differentially
inhibits the recirculation of B cells and subpopulations
of T cells from the LNs to the peripheral blood, with its
greatest effect being on CD4+ T cells and its least effect
being on B cells. As expected, the total number of lym-
phocytes in the blood was significantly reduced, but T
cells were affected more than B cells and CD4 cells more
than CD8 cells. Studies by others indicate that the small
numbers of T cells that remain in the peripheral blood
of FTY720-treated mice are predominantly activated and
memory cells [19]. Changes in lymphocyte composition
were less dramatic in the LNs where an increase in the
percentage of B cells and a decrease in the percentage of
CD3+ T cells were observed, along with fewer total lym-
phocytes in the LNs of FTY720-treated mice in compari-
son to vehicle-treated mice. While FTY720 stops the
egress of lymphocytes from LNs to the circulatory
system, we found no evidence of increased numbers
of lymphocytes in the LNs. In fact, our data indicate
that there were fewer lymphocytes in LNs from
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FTY720-treated mice. While the relocation of these
cells from the peripheral blood and LNs to the spleen
seems like a reasonable explanation, we have not yet
been able to confirm this.
Surprisingly, FTY720 did not prevent or reduce the pri-
mary stimulation and clonal expansion of the auto-
immune T-cell response in vivo. Draining LNs from the
FTY720-treated mice contained a higher percentage of
CII-specific autoimmune T cells in comparison to control
mice, although total numbers were similar to controls be-
cause of the smaller LNs in the treated mice. However,
despite their clonal expansion in vivo, the CII-specific T
cells from the FTY720 mice were unresponsive to restim-
ulation with the CII autoantigen in vitro at time points
that represent the peak of in vivo T-cell expansion [28].
While we cannot completely rule out an inhibitory effect
of FTY720 directly on the autoimmune Th cells, primary
stimulation and clonal expansion of the autoimmune T-
cell population following immunization clearly occur in
vivo in the presence of this drug. This lack of proliferative
recall response was not the result of FTY720-altered
antigen-presenting cell function. Antigen-presenting cells
purified from FTY720-treated mice were fully capable of
stimulating CII-specific T cells from untreated mice, and
T cells from FTY720-treated mice remained unresponsive
when stimulated with antigen-presenting cells from un-
treated mice. These results differ somewhat from the re-
sults reported by others who have shown that FTY720
alters the function of dendritic cells, rendering them tol-
erogenic for T cells [34, 35]. The antigen-presenting cells
from the FTY720-treated animals in our study were de-
rived from LN cells and were not solely dendritic cells.
Collectively, this population of antigen-presenting cells
functioned sufficiently to restimulate the CII-specific T
cells from untreated mice, indicating no loss of function
due to treatment with FTY720. Taken together, these data
imply that the CII-specific T cells from the treated mice
were anergic, and this concept was supported by the re-
versal of their unresponsive state by the addition of IL-2
to the antigen stimulation assays.
Our data and recent studies by others [20, 24, 36] indi-
cate that FTY720 has an effect on Treg cell function. Ana-
lysis of LN cells of FTY720-treated mice revealed that the
percentage of CD4+CD25+Foxp3+ Treg cells was twofold
higher in comparison to the percentage in control ani-
mals, and this resulted in a 2.5 times higher ratio of Treg/
Th cells in vivo. In addition, the function of the Treg cells
from FTY720-treated mice was enhanced on a per-cell
basis compared with Treg cells from control mice. That
these FTY720-mediated changes in Treg cells played a
major role in the regulation of the CII-specific T-cell re-
sponse and the inhibition of autoimmune arthritis was
demonstrated by our Treg depletion studies. Depletion of
Treg cells in vivo before FTY720 treatment and disease
induction prevented the induction of anergy in the CII-
specific T cells and neutralized the FTY720 inhibition of
autoimmune arthritis. Thus, it appears that the increased
Treg ratio and enhanced regulatory function of Treg cells
are a major mechanism by which FTY720 inhibits the
development of autoimmune arthritis in this model. The
Treg depletion studies also indicate that FTY720 does not
directly turn off Th cells, as Treg-depleted FTY720-
treated mice developed a significantly higher incidence of
disease in comparison to the FTY720-treated nondepleted
mice, and anti-CD25 treatment in the presence of FTY720
completely restored the T-cell proliferative response.
These data are consistent with the observations that S1P
binding to S1PR delivers a negative signal to Treg cells
that inhibits not only their generation but also their regu-
latory activity by inducing activation of the Akt/mamma-
lian target of rapamycin (mTOR) pathway [15, 37]. This
conclusion is also supported by studies demonstrating that
mice deficient in expression of S1P1R have increased
numbers of nTreg cells, whereas Tg overexpression of
S1P1R greatly reduces the numbers of Treg cells, and
these S1P1 Tg mice develop systemic autoimmunity [37].
Finally, this relationship between S1P/S1PR binding and
the downregulation of Treg activity may be a significant
factor in the pathogenesis of RA. Synovial fluid from af-
fected joints of patients with RA has high concentrations
of S1P [38]. Given that the activity of Treg cells from the
RA synovium is low [39], it is likely that S1P binding
to Treg cells is at least one mechanism by which the
Treg function in RA is downregulated, thus enabling the
perpetuation of the autoimmune T-cell response in this
disease.
Conclusions
In addition to preventing the recirculation of lympho-
cytes from the LNs to the peripheral blood, FTY720 ap-
pears to have a significant effect on the function of
lymphocytes. As a partial agonist for S1PR, FTY720 dif-
ferentially alters B-cell and T-cell trafficking and both in-
creases the Treg/Th ratio in LNs and enhances the
regulatory function of the Treg cells. Similarly, there ap-
pears to be a differential effect of S1P binding to S1P1R
expressed on Treg and naive T cells. Binding of S1P by
conventional T cells quickly downregulates S1P1R ex-
pression, while Treg expression of S1P1R is slowly re-
duced [37]. S1P binding inhibits the suppressive activity
of nTreg and induced Treg cells by inducing activation
of the Akt/mTOR pathway [15]. The net effect appears
to be that, during an immune response, Treg cell func-
tion is suppressed longer while activation of naive T cells
progresses quickly. FTY720 blocks the binding of S1P,
essentially reversing the homeostatic state; that is, Treg
cell function is upregulated. Therapeutically, the net
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effect is suppression of the Th cell response, a goal in
the treatment of autoimmune diseases.
In our studies, FTY720 was an effective therapeutic
agent for the inhibition of autoimmune arthritis, redu-
cing both the severity and the incidence of disease. This
drug had the most pronounced effect on the recircula-
tion of CD3+CD4+ cells, reducing their levels to <10 %
in the peripheral blood. Surprisingly, FTY720 did not in-
hibit the in vivo generation of the clonally expanded
population of CII-specific autoimmune T cells. However,
at their peak expansion in vivo, these T cells were unre-
sponsive to restimulation in vitro. Given the higher
Treg/Th ratio in the LNs and the enhanced function of
the Treg cells from the FTY720-treated mice, our data
indicate that at least one significant mechanism by
which this drug inhibits disease is through Treg cells.
While FTY720 has been shown to be useful clinically for
multiple sclerosis [22, 23], systemic administration of
this drug has potential deleterious side effects that have
to be monitored. Currently, it is considered a second
line of defense drug for the treatment of multiple scler-
osis, in part because of these concerns. Given our and
others’ determination that this drug potentiates Treg ac-
tivity, a means of site- or cell-specific delivery of this
drug to Treg cells may be its most beneficial use in the
treatment of autoimmunity. Such an approach would
likely decrease the amount of drug required for treat-
ment as well as improve the overall efficacy of FTY720
in the treatment of autoimmune diseases.
Additional file
Additional file 1: Specificity of DR1-CII tetramer for binding to
DR1-restricted, CII-specific, CD4+ T cells. T cells specific for the CII257–274
or HA306–318 peptides were incubated with the DR1-CII tetramer labeled
with PE as described in the Methods section, washed, and analyzed by
flow cytometry. A minimum of 10,000 cells were analyzed, and the data
were gated using forward scatter vs. 90-degree light scatter. a CII257–274-
specific T-cell hybridoma DR1-CII-E174 and HA306–318-specific T-cell
hybridoma DR1-HA-8. Only the CII-specific hybridoma bound the DR1-CII
tetramer. b CII257–274-specific T-cell hybridoma DR1-CII-18 and HA306–318-
specific T-cell hybridoma DR1-HA-3. Only the CII-specific hybridoma
bound the DR1-CII tetramer. (DOC 63 kb)
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